Strs Ohio Makes New Investment in Fulcrum Therapeutics, Inc. $FULC

Strs Ohio acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 91,200 shares of the company’s stock, valued at approximately $263,000. Strs Ohio owned about 0.17% of Fulcrum Therapeutics as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nantahala Capital Management LLC boosted its holdings in Fulcrum Therapeutics by 0.9% during the first quarter. Nantahala Capital Management LLC now owns 4,822,693 shares of the company’s stock worth $13,889,000 after buying an additional 42,985 shares in the last quarter. Exome Asset Management LLC grew its holdings in Fulcrum Therapeutics by 143.0% in the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after purchasing an additional 405,538 shares during the period. ADAR1 Capital Management LLC grew its holdings in Fulcrum Therapeutics by 150.0% in the first quarter. ADAR1 Capital Management LLC now owns 490,532 shares of the company’s stock valued at $1,413,000 after purchasing an additional 294,284 shares during the period. Acadian Asset Management LLC grew its holdings in Fulcrum Therapeutics by 865.0% in the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after purchasing an additional 308,854 shares during the period. Finally, Nuveen LLC purchased a new stake in Fulcrum Therapeutics during the first quarter worth approximately $441,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

FULC has been the subject of several analyst reports. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Piper Sandler reissued an “overweight” rating and set a $9.00 target price (up from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Royal Bank Of Canada increased their price objective on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a report on Wednesday, July 30th. Finally, HC Wainwright raised shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $4.00 to $12.00 in a report on Tuesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $9.60.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $8.25 on Thursday. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $8.50. The company has a 50-day moving average of $7.03 and a two-hundred day moving average of $5.81. The stock has a market cap of $446.24 million, a price-to-earnings ratio of -6.76 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. Analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.